Beijing SL Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Equivalents	644.08	519.4	411.96	683.83	595.04	827.84
Short-Term Investments	-	122.98	1,089	840.62	713.36	646.23
Trading Asset Securities	512.01	498.95	480.86	608.56	144.91	162.36
Cash & Short-Term Investments	1,156	1,141	1,982	2,133	1,453	1,636
Cash Growth	3.86%	-42.42%	-7.07%	46.77%	-11.19%	13.41%
Accounts Receivable	83.14	80.93	105.79	200.57	254.86	357.56
Other Receivables	12.09	14.07	15.65	35.25	31.35	21.6
Receivables	95.23	95	121.44	235.82	286.2	379.16
Inventory	555.14	681.81	246.33	144.46	136.82	124.83
Other Current Assets	242.41	175.82	138.8	126.69	121.34	157.31
Total Current Assets	2,049	2,094	2,489	2,640	1,998	2,298
Property, Plant & Equipment	533.32	541.53	514.24	503.34	527.3	604.01
Long-Term Investments	894.4	1,878	1,578	1,573	1,798	1,404
Other Intangible Assets	613.96	633.01	678.58	693.77	526.36	479.46
Long-Term Deferred Tax Assets	49.69	53.7	69.52	-	39.5	27.65
Long-Term Deferred Charges	511.41	503.88	519	451.89	454.42	394.72
Other Long-Term Assets	1,185	367.93	130.49	415.6	532.22	553.25
Total Assets	5,837	6,072	5,979	6,278	5,876	5,760
Accounts Payable	56.88	95.54	122.29	250.76	176.18	191.4
Accrued Expenses	43.24	48.28	45.82	46.93	30.32	31.8
Current Portion of Leases	-	-	-	-	-	0.25
Current Income Taxes Payable	-	0.16	0.18	0	2.61	4.48
Current Unearned Revenue	385.12	491.97	70.53	15.29	27.87	13.33
Other Current Liabilities	120.12	93.64	50.59	60.34	51.85	83.71
Total Current Liabilities	605.36	729.59	289.41	373.33	288.83	324.96
Long-Term Leases	-	-	-	-	-	2.22
Long-Term Unearned Revenue	38.8	41.07	44	47.04	51.38	56.23
Long-Term Deferred Tax Liabilities	91.3	112.83	64.97	47.36	56.39	50.82
Total Liabilities	735.46	883.49	398.37	467.72	396.6	434.23
Common Stock	1,027	1,027	1,027	1,027	1,027	1,027
Additional Paid-In Capital	-	61.55	49.62	49.62	43.85	32.58
Retained Earnings	4,028	4,114	4,482	4,710	4,396	4,265
Comprehensive Income & Other	39.78	-21.77	13.47	13.47	0.67	-12.99
Total Common Equity	5,095	5,181	5,572	5,801	5,468	5,311
Minority Interest	6.04	7.19	8.2	9.42	11.16	14.73
Shareholders' Equity	5,101	5,189	5,581	5,810	5,479	5,326
Total Liabilities & Equity	5,837	6,072	5,979	6,278	5,876	5,760
Total Debt	-	-	-	-	-	2.47
Net Cash (Debt)	1,156	1,141	1,982	2,133	1,453	1,634
Net Cash Growth	3.86%	-42.42%	-7.07%	46.77%	-11.06%	13.67%
Net Cash Per Share	1.15	1.12	1.87	2.10	1.43	1.57
Filing Date Shares Outstanding	1,076	1,027	1,027	1,027	1,027	1,027
Total Common Shares Outstanding	1,076	1,027	1,027	1,027	1,027	1,027
Working Capital	1,444	1,364	2,199	2,267	1,709	1,973
Book Value Per Share	4.73	5.04	5.42	5.65	5.32	5.17
Tangible Book Value	4,481	4,548	4,894	5,107	4,942	4,832
Tangible Book Value Per Share	4.16	4.43	4.76	4.97	4.81	4.70
Buildings	-	447.97	434.54	437.22	430.73	452.32
Machinery	-	485.36	472.98	458.48	435.39	415.76
Construction In Progress	-	135.02	94.92	56.97	64.75	99.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.